Clinical Trial Update: Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 clinical trial from the University of Iowa evaluated a combination of decitabine, temozolomide, and panobinostat for resistant metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacogen (decitabine) (decitabine)
• Farydak (panobinostat) (panobinostat)
• Temodar (temozolomide) (temozolomide)

Snippet

Sponsor: University of Iowa | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-07-02